Cancer Research and Treatment

Original Articles

Chemotherapy in Advanced Gastric Cancer Patients Associated with Disseminated Intravascular Coagulation: In Gyu Hwang, Jin Hwa Choi, Se Hoon Park, Sung Yong Oh, Hyuk-Chan Kwon, Soon Il Lee, Do Hyoung Lim, Gyeong-Won Lee, Jung Hun Kang; Cancer Res Treat. 2014;46(1):27-32. Published online January 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.1.27

PURPOSE
Little is known about the clinical features of advanced gastric cancer (AGC) combined with disseminated intravascular coagulation (DIC). The main objective of this study was to determine the clinical outcome of patients with AGC complicated by DIC.
MATERIALS AND METHODS
We conducted a retrospective review of 68 AGC patients diagnosed with DIC at four tertiary medical centers between January 1995 and June 2010.
RESULTS
Sixty eight patients were included. The median age was 55 years (range, 25 to 78 years). Nineteen patients received chemotherapy, whereas 49 patients received only best supportive care (BSC). The median overall survival (OS) of the 68 patients was 16 days (95% confidence interval [CI], 11 to 21 days). Significantly prolonged OS was observed in the chemotherapy group, with a median survival of 61 days compared to 9 days in the BSC group (p<0.001, log-rank test). Age and previous chemotherapy were another significant factors that were associated with OS in univariate analysis. In multivariate analysis, age (> or =65 vs. <65; hazard ratio [HR], 0.38; 95% CI, 0.18 to 0.78; p<0.001), chemotherapy (BSC vs. chemotherapy; HR 0.31; 95% CI, 0.15 to 0.63; p<0.001), and previous chemotherapy (yes or no; HR, 0.49; 95% CI, 0.25 to 0.98; p<0.045) were consistently independent prognostic factors that impacted OS.
CONCLUSION
Our study showed that patients with AGC complicated by DIC had very poor OS, and suggested that chemotherapy might improve OS of these patients.

Citations

Citations to this article as recorded by

Long-term survival of a patient with gastric cancer with bone marrow metastasis receiving S-1 plus oxaliplatin beyond three years: a case report and literature review
Hirotaka Suto, Yumiko Inui, Atsuo Okamura
Frontiers in Oncology.2024;[Epub] CrossRef
Metastatic gastric adenocarcinoma discovered in the bone marrow
Ekaterina Proskuriakova, Vaisny Balamurali, Anuradha Hooda, Paramjeet Khosla
BMJ Case Reports.2024; 17(9): e260217. CrossRef
Case report: PD-1 inhibitor-based treatment strategies in gastric cancer complicated by bone marrow metastasis and disseminated intravascular coagulation: A report of two cases
Ren-Ze Huang, Nuo Chen, Yan Hu, Wan-Ming Hu, Feng-Hua Wang, Dong-Liang Chen
Frontiers in Oncology.2023;[Epub] CrossRef
Comparative analysis of systemic oncological treatments and best supportive care for advanced gastresophageal cancer: A comprehensive scoping review and evidence map
Santero Marilina, Meade Adriana, Selva Anna, Acosta‐Dighero Roberto, Meza Nicolás, Quintana Maria Jesús, Bracchiglione Javier, Requeijo Carolina, Salazar Josefina, Rodríguez Grijalva Gerardo, Solà Ivan, Urrútia Gerard, Bonfill Cosp Xavier
Journal of Evidence-Based Medicine.2023; 16(2): 216. CrossRef
Clinicopathologic features and prognosis of 71 patients with gastric cancer and disseminated intravascular coagulation
Ling Chen, Jing Lin, Yu Chen, Jiami Yu, Xiaojie Wang
PeerJ.2023; 11: e16527. CrossRef
Docetaxel and Fluorouracil as First-Line Therapy for Gastric Cancer with Bone Marrow Metastasis and Disseminated Intravascular Coagulation
Zhai Xiaohui, Li Shanshan, Cao Taiyuan, Du Ge, Yu Hongen, Shi Lishuo, Lin Xiaoru, Hong Wanjia, Xiao Jian
Future Oncology.2022; 18(35): 3875. CrossRef
A Clot Waveform Analysis Showing a Hypercoagulable State in Patients with Malignant Neoplasms
Mayu Kobayashi, Hideo Wada, Shunsuke Fukui, Hiroki Mizutani, Yuhuko Ichikawa, Katsuya Shiraki, Isao Moritani, Hidekazu Inoue, Motomu Shimaoka, Hideto Shimpo
Journal of Clinical Medicine.2021; 10(22): 5352. CrossRef
Understanding and treating solid tumor–related disseminated intravascular coagulation in the “era” of targeted cancer therapies
Felice Vito Vitale, Giuseppe SA Longo-Sorbello, Stefano Rotondo, Francesco Ferrau
SAGE Open Medicine.2017;[Epub] CrossRef
Advanced gastric cancer linitis plastica presented with disseminated intravascular coagulation
Sehem Ghazala, Jawad Bilal, Irbaz Bin Riaz
BMJ Case Reports.2016; : bcr2016217675. CrossRef
Efficacy and Safety of Weekly Paclitaxel Therapy for Advanced Gastric Cancer Patients with Disseminated Intravascular Coagulation
Sadayuki Kawai, Yasuhiro Sakamoto, Yoshikazu Takahashi, Sonoko Ichikawa, Makio Gamoh
Journal of Gastrointestinal Cancer.2015; 46(4): 438. CrossRef
D-Dimer Can Serve as a Prognostic and Predictive Biomarker for Metastatic Gastric Cancer Treated by Chemotherapy
Se-Il Go, Min Jeong Lee, Won Sup Lee, Hye Jung Choi, Un Seok Lee, Rock Bum Kim, Myoung Hee Kang, Hoon-Gu Kim, Gyeong-Won Lee, Jung Hun Kang, Jeong-Hee Lee, Sun Joo Kim
Medicine.2015; 94(30): e951. CrossRef

13,825 View
103 Download
13 Web of Science
11 Crossref

A Phase II Study of Modified FOLFOX4 for Colorectal Cancer Patients with Peritoneal Carcinomatosis: Dong Hyun Lee, Sung Yong Oh, Yu Rim Lee, Seok Jae Huh, Hyun Hwa Yoon, Sung Hyun Kim, Suee Lee, Ji Hyun Lee, Young Kim, Hyo-Jin Kim, Hyuk-Chan Kwon; Cancer Res Treat. 2011;43(4):225-230. Published online December 27, 2011; DOI: https://doi.org/10.4143/crt.2011.43.4.225

Abstract PDF PubReader ePub

PURPOSE
Peritoneal carcinomatosis (PC) of colorectal cancer (CRC) is common and is the second most common cause of death. Clinical studies regarding chemotherapy for CRC with PC have been classically rather limited in scope. We evaluated the efficacy of modified oxaliplatin, leucovorin, and fluorouracil (m-FOLFOX4) regimen for PC of CRC origin.
MATERIALS AND METHODS
CRC patients with PC were treated with cycles of oxaliplatin at 85 mg/m2 on day 1, leucovorin 20 mg/m2 followed by 5-fluorouracil (5-FU) via a 400 mg/m2 bolus and a 22 hours continuous infusion of 600 mg/m2 5-FU on days 1-2 at 2-week intervals.
RESULTS
Forty patients participated in this study. Median age was 55 years. Thirty-two patients (80.0%) received previous operation, and 60.0% of PC occurred synchronously. Thirty-five patients (87.5%) were assessable and exhibited measurable lesions. Two patients (5.7%) demonstrated complete response and five patients (14.3%) showed partial response. The median time to progression was 4.4 months (95% confidence interval, 2.5 to 6.3 months), the median overall survival time was 21.5 months (95% confidence interval, 17.2 to 25.7 months). There was no treatment related death. Presence of liver metastasis (p=0.022), performance status (p=0.039), and carcinoembryonic antigen level (p=0.016) were related to the time to progression. Patients with low carcinoembryonic antigen level (37.2 months vs. 15.6 months, p=0.001) or good performance status (22.5 months vs. 6.8 months, p=0.040) showed better overall survival.
CONCLUSION
The m-FOLFOX4 regimen was determined to be effective for CRC patients with PC.

Citations

Citations to this article as recorded by

Results of complete cytoreductive strategy in patients with peritoneal metastases of colorectal origin with or without extraperitoneal metastases: A bicentric analysis
Isabelle Sourrouille, Clément Pastier, Maximilliano Gelli, Léonor Benhaïm, Pierre Cattan, Michel Ducreux, Thomas Aparicio, Diane Goéré
European Journal of Surgical Oncology.2025; 51(1): 108788. CrossRef
Review of systemic chemotherapy in unresectable colorectal peritoneal carcinomatosis
Udit Nindra, Adel Shahnam, Kate L. Mahon
Asia-Pacific Journal of Clinical Oncology.2022; 18(1): 7. CrossRef
Perioperative Systemic Chemotherapy, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: Results of the Prospective Multicenter Phase 2 COMBATAC Trial
Gabriel Glockzin, Florian Zeman, Roland S. Croner, Alfred Königsrainer, Jörg Pelz, Michael A. Ströhlein, Beate Rau, Dirk Arnold, Michael Koller, Hans J. Schlitt, Pompiliu Piso
Clinical Colorectal Cancer.2018; 17(4): 285. CrossRef
Treatment of peritoneal metastases from small bowel adenocarcinoma
Koen P. Rovers, Eelco de Bree, Yutaka Yonemura, Ignace H. de Hingh
International Journal of Hyperthermia.2017; 33(5): 571. CrossRef
Percutaneous lung ablation of pulmonary recurrence may improve survival in selected patients undergoing cytoreductive surgery for colorectal cancer with peritoneal carcinomatosis
T.A. Bin Traiki, O.M. Fisher, S.J. Valle, R.N. Parikh, M.A. Kozman, D. Glenn, M. Power, W. Liauw, N.A. Alzahrani, D.L. Morris
European Journal of Surgical Oncology (EJSO).2017; 43(10): 1939. CrossRef
Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis
C. Demtröder, W. Solass, J. Zieren, D. Strumberg, U. Giger‐Pabst, M.‐A. Reymond
Colorectal Disease.2016; 18(4): 364. CrossRef
Therapeutic options for peritoneal metastasis arising from colorectal cancer
Gabriel Glockzin, Hans J Schlitt, Pompiliu Piso
World Journal of Gastrointestinal Pharmacology and Therapeutics.2016; 7(3): 343. CrossRef
Challenges in the multidisciplinary management of stage IV colon and rectal cancer
Pompiliu Piso, Dirk Arnold, Gabriel Glockzin
Expert Review of Gastroenterology & Hepatology.2015; 9(3): 317. CrossRef
Oxaliplatin-based versus irinotecan-based hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: a retrospective analysis
Gabriel Glockzin, Michael Gerken, Sven A Lang, Monika Klinkhammer-Schalke, Pompiliu Piso, Hans J Schlitt
BMC Cancer.2014;[Epub] CrossRef
Should isolated peritoneal carcinomatosis from colorectal cancer be sub-classified into stage IVB in era of modern chemotherapy?
H. Ishida, K. Kumamoto, K. Ishibashi, S. Hatano, T. Matsuzawa, N. Okada, Y. Kumagai, H. Baba, N. Haga
Techniques in Coloproctology.2013; 17(6): 647. CrossRef
Peritoneal carcinomatosis of colorectal origin: is it really an end-stage disease?
E. Chouillard, V. Greco, N. Tsiminikakis
Techniques in Coloproctology.2013; 17(6): 619. CrossRef
Peritoneal carcinomatosis from colorectal cancer: hyperthermic intraperitoneal chemotherapy and the role of systemic chemotherapy
Michael Michael
Colorectal Cancer.2013; 2(5): 449. CrossRef
Role of Chemotherapy in Peritoneal Carcinomatosis in Metastatic Colorectal Cancer
Jan Franko, Charles D. Goldman, Kiran K. Turaga
Current Colorectal Cancer Reports.2013; 9(3): 242. CrossRef
A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial
Gabriel Glockzin, Justine Rochon, Dirk Arnold, Sven A Lang, Frank Klebl, Florian Zeman, Michael Koller, Hans J Schlitt, Pompiliu Piso
BMC Cancer.2013;[Epub] CrossRef
A Long Survived Case of Transverse Colon Cancer with Peritoneal Dissemination Treated by Multidisciplinary Treatment Including Hyperthermic Intraperitoneal Chemotherapy
Toshiyuki Nakazawa, Takanori Goi, Mituhiro Morikawa, Kenji Koneri, Makoto Murakami, Yasuo Hirono, Atushi Iida, Kanji Katayama, Akio Yamaguchi, Atomu Murai
Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons).2012; 37(6): 1136. CrossRef

11,879 View
63 Download
15 Crossref

Predictive Value of In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay in Advanced Gastric Cancer Patients Who Received Oral 5-Fluorouracil after Curative Resection: Ji Hyun Lee, Min-Chan Kim, Sung Yong Oh, Hyuk-Chan Kwon, Sung-Hyun Kim, Kyung A Kwon, Suee Lee, Jin Sook Jeong, Seok-Reyol Choi, Hyo-Jin Kim; Cancer Res Treat. 2011;43(2):117-123. Published online June 30, 2011; DOI: https://doi.org/10.4143/crt.2011.43.2.117

Abstract PDF PubReader ePub

PURPOSE
To assess the usefulness of adenosine triphosphate-based chemotherapy response assay (ATP-CRA) results in advanced gastric cancer patients receiving adjuvant chemotherapy.
MATERIALS AND METHODS
Sixty-two patients underwent curative surgical resection between January, 2006 and December, 2008. Their highly purified surgical specimens were evaluated by ATP-CRAs. Of the 62, 49 had successful assay results and they received either oral 5-fluorouracil or other chemotherapies. We retrospectively analyzed data for 24 patients who were treated with oral 5-fluorouracil and whose assays were successful.
RESULTS
The median observation time was 24.6 months (range, 10.1 to 40.9 months). The median treatment time was 11.2 months (range, 1.2 to 17.7 months). The median age was 66 years (range, 30 to 81 years). Patients were grouped into sensitive- and resistant-groups according to adenosine triphosphate-based chemotherapy response results for fluorouracil. The sensitive-group showed a significantly longer time to relapse (not reached in the sensitive-group vs. 24.8 months in the resistant-group, p=0.043) and longer overall survival compared to the resistant-group (not reached in the sensitive-group vs. 35.7 months in the resistant-group, p=0.16, statistically insignificant).
CONCLUSION
Patients who receive curative surgical resection significantly benefit from sensitive adjuvant chemotherapy according to ATP-CRA results for time to relapse.

Citations

Citations to this article as recorded by

In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer
Hye Youn Kwon, Im-kyung Kim, Jeonghyun Kang, Seung-Kook Sohn, Kang Young Lee
Cancer Research and Treatment.2016; 48(3): 970. CrossRef
Clinical correlation between <i>in vitro</i> chemoresponse assay and first line chemotherapy for metastatic colorectal cancer patients
Sang Hun Jung, So Hyun Kim, Jae Hwang Kim
Korean Journal of Clinical Oncology.2015; 11(2): 51. CrossRef
Purinergic signalling in the gastrointestinal tract and related organs in health and disease
Geoffrey Burnstock
Purinergic Signalling.2014; 10(1): 3. CrossRef
Establishment of 5-fluorouracil-resistant oral squamous cell carcinoma cell lines with epithelial to mesenchymal transition changes
KOJI HARADA, TARANNUM FERDOUS, YOSHIYA UEYAMA
International Journal of Oncology.2014; 44(4): 1302. CrossRef
Purinergic signalling and cancer
Geoffrey Burnstock, Francesco Di Virgilio
Purinergic Signalling.2013; 9(4): 491. CrossRef
Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines
KAZUYA UCHIBORI, ATSUSHI KASAMATSU, MASAHIKO SUNAGA, SATOSHI YOKOTA, TOMOYA SAKURADA, ERIKO KOBAYASHI, MASAHARU YOSHIKAWA, KATSUHIRO UZAWA, SHIRO UEDA, HIDEKI TANZAWA, NOBUNORI SATO
International Journal of Oncology.2012; 40(4): 1005. CrossRef

11,622 View
46 Download
6 Crossref

Case Report

A Case of 5-Fluorouracil Induced Encephalopathy: Kyung A Kwon, Hyuk-Chan Kwon, Min Chan Kim, Sung-Hyun Kim, Sung Yong Oh, Suee Lee, Hyo-Jin Kim; Cancer Res Treat. 2010;42(2):118-120. Published online June 30, 2010; DOI: https://doi.org/10.4143/crt.2010.42.2.118

Abstract PDF PubReader ePub

Patients with reduced dihydropyrimidine dehydrogenase (DPD) activity are at risk for experiencing serious adverse effects following 5-fluorouracil (5-FU) based chemotherapy. Neurotoxicity is considered an extremely rare side effect of 5-FU. We report here on an unusual case of 5-FU induced encephalopathy. A 38-year-old woman with advanced gastric carcinoma was treated with adjuvant chemotherapy that consisted of infused 5-FU (1,000 mg/m²) for 5 days and cisplatin (60 mg/m²) on day 1 following total gastrectomy. Nineteen days after starting chemotherapy, the patient displayed a sudden onset of slurred speech, confusion, cognitive disturbances and paranoia. A magnetic resonance image (MRI) of the brain showed no structural abnormalities, and the other laboratory tests provided no explanations for her symptoms, other than a slightly elevated ammonia level. The patient was treated with a lactulose retention enema and thiamine infusion, the 5-FU was halted and her symptoms then recovered after 7 days.

Citations

Citations to this article as recorded by

Four decades of chemotherapy-induced cognitive dysfunction: comprehensive review of clinical, animal and in vitro studies, and insights of key initiating events
Ana Dias-Carvalho, Mariana Ferreira, Rita Ferreira, Maria de Lourdes Bastos, Susana Isabel Sá, João Paulo Capela, Félix Carvalho, Vera Marisa Costa
Archives of Toxicology.2022; 96(1): 11. CrossRef
Chemotherapy-Induced Acute Reversible Toxic Leukoencephalopathy
A. K. Vishnu, Thara Pratap, Dhanya Jacob, Muhammed Jasim Abdul Jalal, Anupama Gopalakrishnabhakthan
Current Medical Issues.2022; 20(3): 194. CrossRef
Hyperammonemic encephalopathy associated with 5-fluorouracil in a patient with previous orthotopic liver transplantation
Hemnishil K. Marella, Rahul Peravali, Amit L. Jain, Satheesh Nair, Benedict Maliakkal, Uchenna Agbim, Rajanshu Verma
Baylor University Medical Center Proceedings.2020; 33(2): 256. CrossRef
Neurotoxicity of antineoplastic drugs: Mechanisms, susceptibility, and neuroprotective strategies
Claudia Pellacani, Georgios Eleftheriou
Advances in Medical Sciences.2020; 65(2): 265. CrossRef
Thiamine deficiency in the outpatient psychiatric oncology setting: A case series
Rose Zhang, Sudhakar Tummala, Deepti Chopra
Palliative and Supportive Care.2020; 18(5): 609. CrossRef
5-Fluorouracil rechallenge after 5-fluorouracil-induced hyperammonemic encephalopathy
Alice Boilève, Camille Wicker, Benjamin Verret, Florence Leroy, David Malka, Mathieu Jozwiak, Clément Pontoizeau, Chris Ottolenghi, Pascale De Lonlay, Michel Ducreux, Antoine Hollebecque
Anti-Cancer Drugs.2019; 30(3): 313. CrossRef
An imaging-based review of systemic therapies and associated toxicities in metastatic pancreatic cancer as per the 2018 ASCO guidelines: what every radiologist should know
Daniel A. Smith, Bhanusupriya Somarouthu, Nikhil H. Ramaiya
Abdominal Radiology.2019; 44(6): 2182. CrossRef
A case of acute leukoencephalopathy induced by a combination of 5-fluorouracil and metronidazole
Tatsuya Fukumoto, Fumiaki Katada, Susumu Sato, Hidehiro Shibayama, Shigeo Murayama, Toshio Fukutake
Rinsho Shinkeigaku.2018; 58(2): 118. CrossRef
The successful treatment of 5-fluorouracil (5-FU) overdose in a patient with malignancy and HIV/AIDS with uridine triacetate
Cynthia Santos, Brent W. Morgan, Robert J. Geller
The American Journal of Emergency Medicine.2017; 35(5): 802.e7. CrossRef
Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach
Michele Boisdron-Celle, Olivier Capitain, Roger Faroux, Christophe Borg, Jean Philippe Metges, Marie Pierre Galais, Mehdi Kaassis, Jaafar Bennouna, Karine Bouhier-Leporrier, Eric Francois, Isabelle Baumgaertner, Véronique Guerin-Meyer, Oana Cojocarasu, Ce
Seminars in Oncology.2017; 44(1): 13. CrossRef
Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy
Seiichiro Mitani, Shigenori Kadowaki, Azusa Komori, Keiji Sugiyama, Yukiya Narita, Hiroya Taniguchi, Takashi Ura, Masashi Ando, Yozo Sato, Hidekazu Yamaura, Yoshitaka Inaba, Makoto Ishihara, Tsutomu Tanaka, Masahiro Tajika, Kei Muro
Medicine.2017; 96(22): e6874. CrossRef
Chemotherapy induced stroke mimic: 5-Fluorouracil encephalopathy fulfilling criteria for tissue plasminogen activator therapy
May Thuy Nguyen, Robyn Stoianovici, Luigi Brunetti
The American Journal of Emergency Medicine.2017; 35(9): 1389. CrossRef
Cancer screening and treatment in patients with end-stage renal disease: remaining issues in the field of onco-nephrology
Yuichiro Kitai, Takeshi Matsubara, Taro Funakoshi, Takahiro Horimatsu, Manabu Muto, Motoko Yanagita
Renal Replacement Therapy.2016;[Epub] CrossRef
Reversible slurred speech related to capecitabine and lapatinib combination in patients with breast cancer
Hasan Mutlu, Abdullah Büyükçelik, Zeki Akça, Abdülsamet Erden
Journal of Oncology Pharmacy Practice.2015; 21(1): 72. CrossRef
Subacute reversible toxic encephalopathy related to treatment with capecitabine: A case report with literature review and discussion of pathophysiology
E. Lyros, S. Walter, I. Keller, P. Papanagiotou, K. Fassbender
NeuroToxicology.2014; 42: 8. CrossRef
Epilepsy in women with gynecologic malignancies
Yixue Gu, Qin Yang, Xuefeng Wang
Expert Review of Neurotherapeutics.2014; 14(5): 503. CrossRef
Posterior Reversible Encephalopathy Syndrome (PRES) After Treatment With Oxaliplatin and 5-Fluorouracil
Nicholas Truman, Daniel Nethercott
Clinical Colorectal Cancer.2013; 12(1): 70. CrossRef
5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases
Pierre-Yves Cordier, André Nau, Joseph Ciccolini, Manuela Oliver, Cédric Mercier, Bruno Lacarelle, Eric Peytel
Cancer Chemotherapy and Pharmacology.2011; 68(3): 823. CrossRef

11,449 View
97 Download
18 Crossref

Original Articles

Phase II Study of Gemcitabine plus Cisplatin in Patients with Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer: Jung Hwan Kim, Sung Yong Oh, Hyuk-Chan Kwon, Suee Lee, Sung-Hyun Kim, Dae-Cheol Kim, Jin-Hwa Lee, Hyung-Sik Lee, Se-Heun Cho, Hyo-Jin Kim; Cancer Res Treat. 2008;40(3):101-105. Published online September 30, 2008; DOI: https://doi.org/10.4143/crt.2008.40.3.101

Abstract PDF PubReader ePub

Purpose

Metastatic breast cancer patients are usually exposed to taxane and anthracycline as neoadjuvant, adjuvant and palliative chemotherapeutic agents. This study was designed to determine the efficacy and safety of the use of a gemcitabine and cisplatin (GP) combination treatment in patients with metastatic breast cancer that were pretreated with anthracycline and taxane.

Materials and Methods

We evaluated the use of a GP regimen (1,000 mg/m² gemcitabine administered on days 1 and 8 plus 60 mg/m² cisplatin administered on day 1 every 3 weeks) in 38 breast cancer patients who had received prior chemotherapy with anthracycline and taxane as an adjuvant or neoadjuvant therapy, or as a palliative therapy.

Results

The median patient age was 49 years (age range, 35~69 years). The overall response rate was 28.9% in 11 patients (95% confidence interval [CI], 14~44%). The median time to progression was 5.2 months (95% CI, 3.6~6.8 months). Median survival was 19.5 months (95% CI, 11.2~27.8 months). Major grade 3/4 hematological toxicity was due to leukopenia (36 of 157 cycles, 23.1%). Non-hematological toxicity was rarely severe; grade1/2 nausea and vomiting were observed in 37.8% of the patients. There were no treatment related deaths.

Conclusions

Our results suggest that the use of gemcitabine plus cisplatin appears to be effective and has an acceptable toxicity profile in patients with advanced breast cancer that have been pretreated with anthracycline and taxane.

Citations

Citations to this article as recorded by

Maintenance chemotherapy after 6 cycles of platinum-doublet regimen in anthracycline-and taxane-pretreated metastatic breast cancer
Eun Kyo Joung, Ji Hyun Yang, Sooeun Oh, Se Jun Park, Jieun Lee
The Korean Journal of Internal Medicine.2021; 36(1): 182. CrossRef
Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia
Jinfeng Zhang, Mingxi Lin, Yizi Jin, Linhan Gu, Ting Li, Baoying Yuan, Biyun Wang, Leiping Wang, Sheng Zhang, Jun Cao, Zhonghua Tao, Jian Zhang, Xichun Hu
Breast Cancer Research and Treatment.2020; 182(3): 719. CrossRef
Outcomes of Palliative Weekly Low-Dose Gemcitabine-Cisplatin Chemotherapy in Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer Patients
Jung Sun Kim, In Hae Park, Keun Seok Lee, Jungsil Ro
Journal of Breast Cancer.2014; 17(4): 339. CrossRef
A phase 2 study of sequential neoadjuvant chemotherapy with gemcitabine and doxorubicin followed by gemcitabine and cisplatin in patients with large or locally advanced operable breast cancer: results from long-term follow-up
Pramod K. Julka, Raju T. Chacko, Shona Nag, Rajinder Parshad, Aravindan Nair, Chaitanyanand B. Koppiker, Fen Chao Richard Xue, Helen Barraclough, Navreet Dhindsa, Anil Seth, Anurita Majumdar, Tarun Puri
Breast Cancer.2013; 20(4): 357. CrossRef
Gemcitabine and cisplatin combination regimen in patients with anthracycline- and taxane-pretreated metastatic breast cancer
Tao Wang, Shaohua Zhang, Min Zeng, Xinyou Lu, Ge Shen, Shikai Wu, Santai Song, Zefei Jiang
Medical Oncology.2012; 29(1): 56. CrossRef
Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
H J Stemmler, D diGioia, W Freier, H W Tessen, G Gitsch, W Jonat, W Brugger, E Kettner, W Abenhardt, H Tesch, H J Hurtz, S Rösel, O Brudler, V Heinemann
British Journal of Cancer.2011; 104(7): 1071. CrossRef
Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer
Ali I. Shamseddine, Fadi S. Farhat
Chemotherapy.2011; 57(6): 468. CrossRef
Biweekly gemcitabine–paclitaxel, gemcitabine–carboplatin, or gemcitabine–cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial
Binghe Xu, Zefei Jiang, Sung-Bae Kim, Shiying Yu, Jifeng Feng, Artur Malzyner, Auro del Giglio, Hyun C. Chung, Li Jun Shen, Daniel Lee Kay Pen
Breast Cancer.2011; 18(3): 203. CrossRef

10,781 View
68 Download
8 Crossref

Gemcitabine versus Gemcitabine Combined with Cisplatin Treatment Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Analysis: Jae-Hyuk Choi, Sung Yong Oh, Hyuk-Chan Kwon, Jung Hwan Kim, Jae Hoon Lee, Suee Lee, Dong Mee Lee, Sung-Hyun Kim, Myung Hwan Rho, Young-Hoon Kim, Mee-Sook Rho, Hyo-Jin Kim; Cancer Res Treat. 2008;40(1):22-26. Published online March 31, 2008; DOI: https://doi.org/10.4143/crt.2008.40.1.22

Abstract PDF PubReader ePub

Purpose

Gemcitabine is the most active agent to treat unresectable pancreatic cancer. The superiority of combining other drugs with cisplatin is still controversial; therefore, we performed a retrospective analysis of gemcitabine versus gemcitabine combined with cisplatin to determine the treatment outcomes for patients with locally advanced or metastatic pancreatic cancer.

Materials and Methods

From 2001 to 2007, we enrolled 60 patients who were treated with gemcitabine or gemcitabine combined with cisplatin for locally advanced or metastatic pancreatic cancer. Gemcitabine 1, 000 mg/m² (G) was administrated at day 1 and day 8 every 3 weeks. Cisplatin 60 mg/m² was added at day 1 every 3 weeks to the gemcitabine schedule (GP).

Results

Number of G: GP was 34: 26, locally advanced to metastatic ratio was 35% to 65% in group G and 46% to 54% in group GP. Median follow up duration was 29 months. The median number of chemotherapy cycles was 4 (range: 2~11) for the G group, and 4 (range: 1~11) for the GP group. The response rate of the G and GP groups was 17% and 11%, respectively. The progression free survival (PFS) was 4.5 months and 2.8 months, respectively, for the G and GP groups. The overall survival (OS) was 10.7 and 8.7 months respectively, for the G and GP groups, but there is no statistically significant difference of the PFS (p=0.2396) and OS (p=0.4643) between the 2 groups. The hematological toxicity profile was similar (the grade III neutropenia and thrombocytopenia was 4.4% and 3.1%, respectively, in G group, and 7.5% and 2.8%, respectively, in the GP group). But non-hematological toxicities such as skin rash, abnormal liver function and nausea/vomiting were observed in 3 patients of the GP group. On the prognostic factor analysis, no factors predicted a longer PFS and OS for both the G and GP groups.

Conclusions

Gemcitabine single treatment might be more tolerable and it had the same efficacy compared to cisplatin combination treatment in this retrospective study.

Citations

Citations to this article as recorded by

Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies
David J. Kuter
Haematologica.2022; 107(6): 1243. CrossRef
Treatment of drug-induced immune thrombocytopenias
Irene Marini, Gunalp Uzun, Kinan Jamal, Tamam Bakchoul
Haematologica.2022; 107(6): 1264. CrossRef
Concurrent chemotherapy alone versus irreversible electroporation followed by chemotherapy on survival in patients with locally advanced pancreatic cancer
Giuseppe Belfiore, Maria Paola Belfiore, Alfonso Reginelli, Raffaella Capasso, Francesco Romano, Giovanni Pietro Ianniello, Salvatore Cappabianca, Luca Brunese
Medical Oncology.2017;[Epub] CrossRef
Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study
Eric S. Winer, Howard Safran, Boguslawa Karaszewska, Sebastian Bauer, Dilawar Khan, Steffen Doerfel, Paul Burgess, Stacey Kalambakas, Yasser Mostafa Kamel, Frederic Forget
International Journal of Hematology.2017; 106(6): 765. CrossRef
Eltrombopag with gemcitabine‐based chemotherapy in patients with advanced solid tumors: a randomized phase I study
Eric S. Winer, Howard Safran, Boguslawa Karaszewska, Donald A. Richards, Lee Hartner, Frederic Forget, Rodryg Ramlau, Kirushna Kumar, Bhabita Mayer, Brendan M. Johnson, Conrad A. Messam, Yasser Mostafa Kamel
Cancer Medicine.2015; 4(1): 16. CrossRef
Comparison of Gemcitabine Combined With Targeted Agent Therapy Versus Gemcitabine Monotherapy in the Management of Advanced Pancreatic Cancer
Qin Li, Zhenyan Yuan, Han Yan, Zhaoyang Wen, Ruixue Zhang, Bangwei Cao
Clinical Therapeutics.2014; 36(7): 1054. CrossRef
Efficacy and Safety of Gemcitabine-Fluorouracil Combination Therapy in the Management of Advanced Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials
Qin Li, Han Yan, Wenting Liu, Hongchao Zhen, Yifan Yang, Bangwei Cao, Jonathan R. Brody
PLoS ONE.2014; 9(8): e104346. CrossRef
Oncolytic Activity of Avian Influenza Virus in Human Pancreatic Ductal Adenocarcinoma Cell Lines
Samantha B. Kasloff, Matteo S. Pizzuto, Micol Silic-Benussi, Silvia Pavone, Vincenzo Ciminale, Ilaria Capua, K. L. Beemon
Journal of Virology.2014; 88(16): 9321. CrossRef
Triptolide Cooperates With Cisplatin to Induce Apoptosis in Gemcitabine-Resistant Pancreatic Cancer
Wenbo Zhu, Jingjie Li, Sihan Wu, Shifeng Li, Liang Le, Xingwen Su, Pengxin Qiu, Haiyan Hu, Guangmei Yan
Pancreas.2012; 41(7): 1029. CrossRef

11,511 View
57 Download
9 Crossref

Case Reports

Unusual Presentation of Large B Cell Lymphoma- Bone and Stomach- Treated with Autologous Transplantation: Bokyung Kim, Sung Yong Oh, Suee Lee, Hyuk-Chan Kwon, Sung-Hyun Kim, Sook Hee Hong, Sung-Soo Kim, Hyo-Jin Kim; Cancer Res Treat. 2007;39(4):181-184. Published online December 31, 2007; DOI: https://doi.org/10.4143/crt.2007.39.4.181

Abstract PDF PubReader ePub: Extranodal presentation of diffuse large B cell lymphoma (DLBL) is frequently observed in the gastrointestinal tract, CNS, bone, testes and liver. However, the simultaneous detection of multiple extranodal involvement at presentation is quite an uncommon occurrence. In this study, we report on a patient with an uncommon presentation of DLBL, and he had symptoms of left knee joint pain and hematemesis, characterized by bone and stomach involvement. Computed tomography and fluorodeoxyglucose-positron emission tomography (FDG-PET) scanning revealed a rapid, extensive spread to the bones and soft tissues. Subsequent histopathological examination verified the bony and gastric CD20-positive DLBL localization. We diagnosed this case as DLBL of stage IV with an international prognostic index of 3, and classified him into the high intermediate risk group. This patient was treated via chemotherapy with an R-CHOP regimen. After achieving a partial response, the patient received autologous peripheral blood stem cell transplantation. The patient attained partial remission, as shown on the FDG-PET scan, and he displayed improvement of his left femur pain.

9,218 View
50 Download

Extraskeletal Mesenchymal Chondrosarcoma of the Heart Responded to Systemic Chemotherapy: A Case Report: Chien Ter Hsing, Sung Yong Oh, Suee Lee, Hyuk-Chan Kwon, Sung-Hyun Kim, Tae-Ho Park, Jong Soo Woo, Seo Hee Na, Hyo-Jin Kim; Cancer Res Treat. 2007;39(3):131-133. Published online September 30, 2007; DOI: https://doi.org/10.4143/crt.2007.39.3.131

Abstract PDF PubReader ePub

Mesenchymal chondrosarcoma is a rare cartilaginous ne - oplasm of an extraskeletal origin, and this predominately occurs in the head and neck, and also in the lower extremities. Fewer than twenty cases of cardiac mesenchymal chondrosarcoma have so far been reported on. For the most part, the results of treatment for patients with this condition have been dismal. In this study, we describe a case of cardiac mesenchymal chondrosarcoma that responded to chemotherapy following surgical biopsy. A 46-year-old man was referred for evaluation of his pleural effusions in both lungs. Chest computed tomography revealed an ovoid-shaped mass in the posterior wall of the patient's left atrium. The echocardiogram revealed a large ovoid-shaped immobile mass (11×6 cm²) in the pericardiac space, which was attached to the posterior wall of the left atrium. Emergency pericardiostomy with closure thoracostomy was performed. Seven days later, a thoracotomy was performed for reduction and diagnosis of the cardiac mass. The pathological diagnosis was extraskeletal mesenchymal chondrosarcoma of the heart.. Postoperative chemotherapy was performed for the huge remaining mass with a combined regimen of etoposide, ifosfamide and cisplatin. After 6 cycles, the patient showed a partial response without symptoms. Although cardiac mesenchymal chondrosarcoma has been reported to be chemotherapy-resistant with a short survival duration, chemotherapy may prove to be an effective treatment modality.

Citations

Citations to this article as recorded by

Unusual Presentation of Extraskeletal Mesenchymal Chondrosarcoma: A Case Report
Mathilde Bernard, Ramy Samargandi
Cureus.2023;[Epub] CrossRef
Mesenchymal chondrosarcoma: imaging features and clinical findings
Soleen Ghafoor, Meera R. Hameed, William D. Tap, Sinchun Hwang
Skeletal Radiology.2021; 50(2): 333. CrossRef
18F-FDG PET/CT Findings of Mesenchymal Chondrosarcoma of the Orbit
Mitsuteru Tsuchiya, Takayuki Masui, Yoshiro Otsuki, Harumi Sakahara
Clinical Nuclear Medicine.2018; 43(2): e43. CrossRef
Mesenchymal chondrosarcoma of the orbit: imaging features of CT and MRI
Mitsuteru Tsuchiya, Takayuki Masui, Yoshiro Otsuki, Harumi Sakahara
The British Journal of Radiology.2018; 91(1090): 20170579. CrossRef
Radiofrequency ablation of metastatic chondrosarcoma-associated refractory ventricular tachycardia originating from the right ventricular outflow tract: A case report and literature review
Xiangmin Shi, Zhuo Liang, Jian Li, Jianping Guo, Zhaoliang Shan, Yutang Wang
Experimental and Therapeutic Medicine.2016; 12(3): 1803. CrossRef
A Rare Case of Extraskeletal Mesenchymal Chondrosarcoma with Dedifferentiation Arising from the Buccal Space in a Young Male
Shalini R. Gupta, Ravinder K. Saran, Pankaj Sharma, Aadithya B. Urs
Journal of Maxillofacial and Oral Surgery.2015; 14(S1): 293. CrossRef
Mesenchymal Chondrosarcoma of Bone and Soft Tissue: A Systematic Review of 107 Patients in the Past 20 Years
Jie Xu, Dasen Li, Lu Xie, Shun Tang, Wei Guo, David M Loeb
PLOS ONE.2015; 10(4): e0122216. CrossRef
A fatal case of primary cardiac chondrosarcoma presenting with amaurosis fugax
Jens Sundbøll, Nils Henrik Stubkjær Hansson, Steen Baerentzen, Manan Pareek
BMJ Case Reports.2015; : bcr2015212178. CrossRef
Extraskeletal Intraspinal Mesenchymal Chondrosarcoma; 18F-FDG PET/CT Finding
EunSeong Lee, Ho Young Lee, Gheeyoung Choe, Ki-Jeong Kim, Won Woo Lee, Sang Eun Kim
Clinical Nuclear Medicine.2014; 39(1): e64. CrossRef
Management of renal extraskeletal mesenchymal chondrosarcoma
Vitalie Gherman, Ciprian Tomuleasa, Catalina Bungardean, Nicolae Crisan, Victor-Dan Ona, Bogdan Feciche, Alexandru Irimie, Ioan Coman
BMC Surgery.2014;[Epub] CrossRef
Primary Cardiac Chondrosarcoma
Guofei Zhang, Xiaofan Chen, Lei Guo, Qiang Feng, Yiming Ni
Journal of Cardiac Surgery.2012; 27(2): 186. CrossRef

9,631 View
52 Download
11 Crossref

Original Articles

A Phase II Study of Paclitaxel and Cisplatin as Salvage Therapy for Patients with Advanced or Metastatic Gastric Cancer: Bong-Gun Seo, Sung Yong Oh, Dong Mee Lee, Hyun Seung Yoo, Suee Lee, Seong-Geun Kim, Sung-Hyun Kim, Hyuk-Chan Kwon, Hyo-Jin Kim; Cancer Res Treat. 2007;39(1):6-9. Published online March 31, 2007; DOI: https://doi.org/10.4143/crt.2007.39.1.6

Abstract PDF PubReader ePub

Purpose

To evaluate the therapeutic activity and safety of paclitaxel and cisplatin combination chemotherapy in patients with advanced or metastatic gastric cancers that are unresponsive to primary chemotherapy.

Materials and Methods

Advanced or metastatic gastric cancer patients unresponsive to first line chemotherapy were entered into this trial. The treatment regimen consisted of paclitaxel, 175 mg/m² by 3-hour infusion on day 1, and cisplatin, 60 mg/m² by 1 hour infusion on day 1, with the treatment repeated every 3 weeks.

Results

37 patients were entered in this study, with 32 fully evaluable for response. 4 (13%), 13 (40%) and 15 (47%) patients achieved a partial response, stable disease and progressed, respectively. The median time to progression was 4.0 months (95% CI: 2.0~6.0 months), and the median overall survival was 12.6 months (95% CI: 5.5~19.7 months), with a 1-year survival rate of 54%. Of a total of 135 cycles of chemotherapy, grades 3 and 4 hematological toxicities were neutropenia (14%) and anemia (3%). Grade ≥2 neuropathy was observed in 6 patients (17%).

Conclusion

The combination of paclitaxel and cisplatin is an effective and tolerable salvage treatment modality for advanced gastric cancer.

Citations

Citations to this article as recorded by

Treatment Outcome and Safety of the TCX Regimen for Advanced Gastric Cancer: A Prospective Cohort Study
Hieu Trong Nguyen, Kien Hung Do, Nguyen Ba Le, Thang Tran
Cancer Management and Research.2022; Volume 14: 2825. CrossRef
Multi-center Phase II Trial of Weekly Paclitaxel Plus Cisplatin Combination Chemotherapy in Patients with Advanced Gastric and Gastro-esophageal Cancer
Q. Sun, C. Liu, H. Zhong, B. Zhong, H. Xu, W. Shen, D. Wang
Japanese Journal of Clinical Oncology.2009; 39(4): 237. CrossRef

9,286 View
45 Download
2 Crossref

Expressions of Matrix Metalloproteinase-7 and -9 and their Prognostic Significances in Rectal Cancer: Young Rak Cho, Hyuk-Chan Kwon, Sung-Hwan Suh, Jong Hoon Lee, Sung-Hyun Kim, Hong-Jo Choi, Hyung-Sik Lee, Mee Sook Roh, Tae-Ho Hwang, Jae-Seok Kim, Hyo-Jin Kim; Cancer Res Treat. 2005;37(6):354-359. Published online December 31, 2005; DOI: https://doi.org/10.4143/crt.2005.37.6.354

Abstract PDF PubReader ePub

Purpose

The matrix metalloproteinases (MMPs) are a family of proteolytic enzymes. MMPs are known to be involved in tumor invasion, and several have been implicated in tumor prognosis. The aim of this study was to evaluate the prognostic significances of the expressions of MMP-7 and -9 in rectal cancer.

Materials and Methods

The tumor tissues of 87 patients with stage II or III rectal carcinoma that underwent potentially curative resection followed by postoperative adjuvant chemoradiation and 5-fluorouracil based chemotherapy, were investigated immunohistochemically using monoclonal antibodies against MMP-7 and MMP-9. Clinical information, including tumor grades, carcinoembryonic antigen (CEA) levels, and disease-free survival and overall survival were evaluated with respect to the expressions of MMP-7 and -9.

Results

Median follow-up duration was 53.2 months, and median patient age was 55±11 years (range 32~75). MMP-7 expression in tumor tissue was found to be significantly correlated with the presence of nodal metastasis (p=0.029), whilst MMP-9 expression correlated with depth of tumor invasion (p=0.019). No relationships were found between the expressions of MMP-7 or -9 and age, sex, tumor size, tumor grade, or CEA level. Univariate analysis showed that MMP-7 expression was associated with poor 5-year overall survival (12.8 months vs. 65.3 months, p=0.0405). Multivariate analysis confirmed that MMP-7 was independently associated with an adverse outcome (Relative risk: 1.415, p=0.027). However, MMP-9 expression was not found to be related to clinical outcome.

Conclusion

MMP-7 expression in tumor tissue is associated with lymph node metastasis and a poor 5-year overall survival in rectal cancer patients.

Citations

Citations to this article as recorded by

Effects of radiation on the metastatic process
Nora Sundahl, Fréderic Duprez, Piet Ost, Wilfried De Neve, Marc Mareel
Molecular Medicine.2018;[Epub] CrossRef
Prognostic significance of MMP-7 expression in colorectal cancer: A meta-analysis
Da-wei Sun, Ying-yi Zhang, Yue Qi, Xing-tong Zhou, Guo-yue Lv
Cancer Epidemiology.2015; 39(2): 135. CrossRef
Matrix metalloproteinase 9 expression and prognosis in colorectal cancer: a meta-analysis
Chun-Yu Li, Peng Yuan, Shu-Sen Lin, Cheng-Fei Song, Wei-Yu Guan, Lu Yuan, Rong-Bin Lai, Ying Gao, Yan Wang
Tumor Biology.2013; 34(2): 735. CrossRef

9,737 View
68 Download
3 Crossref

Oxaliplatin with Biweekly Low Dose Leucovorin and Bolus and Continuous Infusion of 5-fluorouracil (Modified FOLFOX 4) as a Salvage Therapy for Patients with Advanced Gastric Cancer: Sung-Hwan Suh, Hyuk-Chan Kwon, Ji-Hoon Jo, Young-Rak Cho, Bong-Gun Seo, Dong-Mee Lee, Sung-Hyun Kim, Jae-Seok Kim, Hyo-Jin Kim; Cancer Res Treat. 2005;37(5):279-283. Published online October 31, 2005; DOI: https://doi.org/10.4143/crt.2005.37.5.279

Abstract PDF PubReader ePub

Purpose

To determine the activity and the toxicity associated with a low dose regimen of leucovorin (LV) plus 5-fluorouracil (5-FU) combined with oxaliplatin every two weeks (modified FOLFOX 4) as a salvage therapy for advanced gastric cancer patients.

Materials and Methods

Between December 2003 and December 2004, 33 patients were enrolled in this study. The patients were treated with oxaliplatin 85 mg/m² as a 2-hour infusion on the first day plus LV 20 mg/m² over 10 minutes. Subsequently, the patients were given a 5-FU bolus 400 mg/m² followed by a 22-hour continuous infusion of 600 mg/m² on days 1~2. The treatment was repeated at 2 week intervals.

Results

The median age of the patients was 50 years (range: 31~74), 82% (27/33) had the Eastern Cooperative Oncology Group performance status was 0 and 1. Of the 30 patients who could be evaluated for their tumor response, 8 achieved a partial response, with an overall response rate of 26.7% (95% confidence interval (CI): 20.5~32.7%). Fifteen patients (50%) showed stable disease and 7 patients (23.3%) progressed during the course of treatment. The median time from the start of chemotherapy to progression was 3.5 months (95% CI: 2.6~4.4 months) and the median overall survival time was 7.9 months (95% CI: 5.9~9.9 months). The major grade 3/4 hematological toxicity encountered included neutropenia (45.4%) and thrombocytopenia (3.0%). Neutropenic fever occurred during only 2 of the 178 cycles. The most common non-hematological toxicity encountered was grade 1/2 nausea/vomiting, which occurred in 18.2% of patients, diarrhea in 12.1% and neuropathy in 15.2%. There were no treatment related deaths.

Conclusion

The modified FOLFOX 4 regimen appears to be a safe and effective salvage therapy for advanced gastric cancer patients.

Citations

Citations to this article as recorded by

PrPC Aptamer Conjugated–Gold Nanoparticles for Targeted Delivery of Doxorubicin to Colorectal Cancer Cells
Gyeongyun Go, Chang-Seuk Lee, Yeo Min Yoon, Ji Ho Lim, Tae Hyun Kim, Sang Hun Lee
International Journal of Molecular Sciences.2021; 22(4): 1976. CrossRef
A Phase I Study of Pevonedistat Plus Capecitabine Plus Oxaliplatin in Patients With Advanced Gastric Cancer Refractory to Platinum (NCCH-1811)
Hirokazu Shoji, Daisuke Takahari, Hiroki Hara, Kengo Nagashima, Jun Adachi, Narikazu Boku
Future Science OA.2021;[Epub] CrossRef
Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan
Chihiro Kondoh, Shigenori Kadowaki, Azusa Komori, Yukiya Narita, Hiroya Taniguchi, Takashi Ura, Masashi Ando, Kei Muro
Gastric Cancer.2018; 21(6): 1050. CrossRef
Pemetrexed for previously treated patients with metastatic gastric cancer: a prospective phase II study
D S Zhang, Y Jin, H Y Luo, Z Q Wang, M Z Qiu, F H Wang, Y H Li, R H Xu
British Journal of Cancer.2015; 112(2): 266. CrossRef
Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer
Ji Hyun Lee, Sung-Hyun Kim, Sung Yong Oh, Suee Lee, Hojin Lee, Hye Jung Lee, Hyo-Jin Kim
The Korean Journal of Internal Medicine.2013; 28(3): 314. CrossRef
A Retrospective Study of the Safety and Efficacy of a First-Line Treatment with Modified FOLFOX-4 in Unresectable Advanced or Recurrent Gastric Cancer Patients
Yung-Sung Yeh, Hsiang-Lin Tsai, Cheng-Jen Ma, Deng-Chyang Wu, Chien-Yu Lu, I-Chen Wu, Ming-Feng Hou, Jaw-Yuan Wang
Chemotherapy.2012; 58(5): 411. CrossRef
Modified FOLFOX-6 Therapy for Heavily Pretreated Advanced Gastric Cancer Refractory to Fluorouracil, Irinotecan, Cisplatin and Taxanes: A Retrospective Study
K. Tsuji, H. Yasui, Y. Onozawa, N. Boku, H. Doyama, A. Fukutomi, K. Yamazaki, N. Machida, A. Todaka, H. Taniguchi, T. Tsushima, T. Yokota
Japanese Journal of Clinical Oncology.2012; 42(8): 686. CrossRef
PEG‐liposomal oxaliplatin induces apoptosis in human colorectal cancer cells via Fas/FasL and caspase‐8
Chuang Yang, Hai‐Zhong Liu, Zhong‐Xue Fu
Cell Biology International.2012; 36(3): 289. CrossRef
Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group
J G Kim, S K Sohn, Y S Chae, H S Song, K-Y Kwon, Y R Do, M K Kim, K H Lee, M S Hyun, H M Ryoo, S H Bae, K U Park, W S Lee, J H Baek, H Y Chung, W Yu
British Journal of Cancer.2008; 98(3): 542. CrossRef
A Phase II Study of Paclitaxel and Cisplatin as Salvage Therapy for Patients with Advanced or Metastatic Gastric Cancer
Bong-Gun Seo, Sung Yong Oh, Dong Mee Lee, Hyun Seung Yoo, Suee Lee, Seong-Geun Kim, Sung-Hyun Kim, Hyuk-Chan Kwon, Hyo-Jin Kim
Cancer Research and Treatment.2007; 39(1): 6. CrossRef
Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer
H.-C. Kwon, M.S. Roh, S.Y. Oh, S.-H. Kim, M.C. Kim, J.-S. Kim, H.-J. Kim
Annals of Oncology.2007; 18(3): 504. CrossRef

9,601 View
60 Download
11 Crossref

Intensity of Tumor Budding as an Index for the Malignant Potential in Invasive Rectal Carcinoma: Sang-Sik Ha, Hong-Jo Choi, Ki-Jae Park, Jung-Min Kim, Sung-Heun Kim, Young-Hoon Roh, Hyuk-Chan Kwon, Mee-Sook Roh; Cancer Res Treat. 2005;37(3):177-182. Published online June 30, 2005; DOI: https://doi.org/10.4143/crt.2005.37.3.177

Abstract PDF PubReader ePub

Purpose

The aim of this study was to quantitatively assess the intensity of tumor budding in rectal carcinoma and to determine how it correlates with the malignant potential.

Materials and Methods

Intensities of the tumor budding at the invasive front of the surgical specimens from 90 patients (male, 51) with well- or moderately-differentiated rectal carcinoma were investigated. Differences in the budding intensity among pathologic variables were compared, and recurrences and survivals were analyzed in accordance with degree of the budding intensity. The patients ranged in age from 33 to 75 years (mean, 55.4) with the median follow-up being 43 months (range, 12~108).

Results

Tumor budding was identified in 89 patients (98.9%) with a mean intensity of 7.5±5.3. The budding intensity was significantly higher in tumors with lymphatic invasion (p=0.0081), blood vessel invasion (p<0.0001), and perineural invasion (p=0.0013) than in those tumor without these findings. It became significantly higher with the increase in nodal stage (p<0.0001). The intensity of tumor budding in patients with relapse (29 patients) was significantly higher than that in patients without relapse (6.2±5.0 vs. 10.2±4.9; p=0.0005), but this difference in the intensity was observed only for the node-positive patients (8.0±3.4 vs. 11.9±5.1; p=0.0064). When the patients were stratified into two groups on either side of the mean of the intensity, the higher intensity group showed a significantly less favorable disease-free (DFS) and overall survival (OS) (p=0.0026 and 0.0205, respectively). Based on the multivariate analysis, the nodal stage and the intensity of budding proved to be the independent variables associated with DFS (p=0.023 and 0.03, respectively).

Conclusion

Tumor budding at the invasive margin is a reliable pathologic index that indicates a higher malignant potential and a less favorable prognosis for patients with advanced rectal carcinoma.

Citations

Citations to this article as recorded by

Polyploid giant cancer cells and cancer progression
Xinyue Zhou, Mingming Zhou, Minying Zheng, Shifeng Tian, Xiaohui Yang, Yidi Ning, Yuwei Li, Shiwu Zhang
Frontiers in Cell and Developmental Biology.2022;[Epub] CrossRef
Tumor Budding as a Prognostic Marker in Rectal Cancer Patients on Propensity Score Analysis
Jung Kyong Shin, Yoon Ah Park, Jung Wook Huh, Seong Hyeon Yun, Hee Cheol Kim, Woo Yong Lee, Seok Hyung Kim, Sang Yun Ha, Yong Beom Cho
Annals of Surgical Oncology.2021; 28(13): 8813. CrossRef
Immunohistochemical evaluation of tumor budding for stratifying T1 colorectal cancer: optimal cut-off value and a novel computer-assisted semiautomatic method
Manabu Takamatsu, Hiroshi Kawachi, Noriko Yamamoto, Maki Kobayashi, Yuka Toyama, Takashi Maekawa, Akiko Chino, Shoichi Saito, Masashi Ueno, Yutaka Takazawa, Yuichi Ishikawa
Modern Pathology.2019; 32(5): 675. CrossRef
Tumor Budding: Prognostic Value in Muscle-invasive Bladder Cancer
Laura Lorenzo Soriano, Guzmán Ordaz Jurado, José Luis Pontones Moreno, Sara Villarroya Castillo, Soraya Hernández Girón, Iván Sáez Moreno, David Ramos Soler
Urology.2019; 130: 93. CrossRef
RAS, Cellular Plasticity, and Tumor Budding in Colorectal Cancer
Valeria Maffeis, Lorenzo Nicolè, Rocco Cappellesso
Frontiers in Oncology.2019;[Epub] CrossRef
Prognostic Impact of Tumor-Budding Grade in Stages 1–3 Colon Cancer: A Retrospective Cohort Study
Bo Young Oh, Yoon Ah Park, Jung Wook Huh, Seong Hyeon Yun, Hee Cheol Kim, Ho-Kyung Chun, Seok Hyung Kim, Sang Yun Ha, Woo Yong Lee, Yong Beom Cho
Annals of Surgical Oncology.2018; 25(1): 204. CrossRef
Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching
Linde De Smedt, Sofie Palmans, Daan Andel, Olivier Govaere, Bram Boeckx, Dominiek Smeets, Eva Galle, Jasper Wouters, David Barras, Madeleine Suffiotti, Jeroen Dekervel, Thomas Tousseyn, Gert De Hertogh, Hans Prenen, Sabine Tejpar, Diether Lambrechts, Xavi
British Journal of Cancer.2017; 116(1): 58. CrossRef
Tumour budding in colorectal cancer: what do we know and what can we do?
Linde De Smedt, Sofie Palmans, Xavier Sagaert
Virchows Archiv.2016; 468(4): 397. CrossRef
Tumor Budding: The Name is EMT. Partial EMT.
Alexandru Grigore, Mohit Jolly, Dongya Jia, Mary Farach-Carson, Herbert Levine
Journal of Clinical Medicine.2016; 5(5): 51. CrossRef
The relationship between tumour budding, the tumour microenvironment and survival in patients with primary operable colorectal cancer
Hester C van Wyk, James H Park, Joanne Edwards, Paul G Horgan, Donald C McMillan, James J Going
British Journal of Cancer.2016; 115(2): 156. CrossRef
Tumor Budding, Micropapillary Pattern, and Polyploidy Giant Cancer Cells in Colorectal Cancer: Current Status and Future Prospects
Shiwu Zhang, Dan Zhang, Zhengduo Yang, Xipeng Zhang, Chuanwei Yang
Stem Cells International.2016;[Epub] CrossRef
The role of tumour budding in predicting survival in patients with primary operable colorectal cancer: A systematic review
H.C. van Wyk, James Park, Campbell Roxburgh, Paul Horgan, Alan Foulis, Donald C. McMillan
Cancer Treatment Reviews.2015; 41(2): 151. CrossRef
Tumour Budding and Survival in Stage II Colorectal Cancer: a Systematic Review and Pooled Analysis
F. Petrelli, E. Pezzica, M. Cabiddu, A. Coinu, K. Borgonovo, M. Ghilardi, V. Lonati, D. Corti, S. Barni
Journal of Gastrointestinal Cancer.2015; 46(3): 212. CrossRef
Tumor Budding in Colorectal Carcinoma
Rondell P. Graham, Robert A. Vierkant, Lori S. Tillmans, Alice H. Wang, Peter W. Laird, Daniel J. Weisenberger, Charles F. Lynch, Amy J. French, Susan L. Slager, Yassaman Raissian, Joaquin J. Garcia, Sarah E. Kerr, Hee Eun Lee, Stephen N. Thibodeau, James
American Journal of Surgical Pathology.2015; 39(10): 1340. CrossRef
Tumor budding in the clinical management of colon and rectal cancer
Viktor H Koelzer, Inti Zlobec, Alessandro Lugli
Colorectal Cancer.2014; 3(4): 387. CrossRef
Tumour budding and the expression of cancer stem cell marker aldehyde dehydrogenase 1 in nasopharyngeal carcinoma
Wei‐Ren Luo, Fei Gao, Si‐Yi Li, Kai‐Tai Yao
Histopathology.2012; 61(6): 1072. CrossRef
Tumor budding in colorectal carcinoma: time to take notice
Bojana Mitrovic, David F Schaeffer, Robert H Riddell, Richard Kirsch
Modern Pathology.2012; 25(10): 1315. CrossRef
Prognostic significance of tumor budding in gastrointestinal tumors
Bruno Märkl, Hans M Arnholdt
Expert Review of Anticancer Therapy.2011; 11(10): 1521. CrossRef
The Prognostic Significance of Fascin Expression in Colorectal Carcinoma
Jeong Min Lee, Jong Hun Lee, Mee Sook Roh, Ki Jae Park
Intestinal Research.2010; 8(2): 117. CrossRef

9,707 View
50 Download
19 Crossref

Impact of the New AJCC Staging System and Adjuvant Treatment in Rectal Cancer: Shin Ae Lee, Hyuk-Chan Kwon, Min Ah Park, Chang Kil Jung, Sung-Hyun Kim, Ki-Jae Park, Hong-Jo Choi, Hyung-Sik Lee, Mee Sook Roh, Jae-Seok Kim, Hyo-Jin Kim; Cancer Res Treat. 2004;36(2):121-127. Published online April 30, 2004; DOI: https://doi.org/10.4143/crt.2004.36.2.121

Abstract PDF PubReader ePub

Purpose

The combination of chemoradiation and fluorouracil based chemotherapy has been the standard adjuvant treatment for colorectal cancer patients. The aim of this study was to evaluate treatment outcome of patients classified by the new AJCC staging system and to compare treatment outcome of oral doxifluridine and the standard Mayo Clinic regimen after chemoradiation in advanced rectal cancer patients.

Materials and Methods

One hundred nine patients underwent curative surgical resection and chemoradiation followed by chemotherapy. 45 Gy pelvic irradiation was given to the entire pelvis and the boost radiation with 50.4 to 54 Gy, and simultaneously 5-fluorouracil (5-FU) 375 mg/m²/day was given on day 1~3 and 26~28. After the completion of chemoradiation, patients were given either 6 cycles of the Mayo Clinic regimen (5-FU 425 mg/m² plus leucovorin 20 mg/m² intravenous bolus infusion on day 1~5, every 4 weeks) or oral doxifluridine (600 mg/m²/day) for 1 year.

Results

The median follow-up duration was 30 months. Among 102 evaluable patients, 38 patients (37.3%) relapsed: the locoregional recurrence in 10 patients (9.8%) and systemic relapse in 28 patients (27.5%). The systemic relapse rate was 15.6% in the stage IIA, 25.0% in the stage IIIB , and 59.1% in the stage IIIC (p=0.048). The 5-year disease-free survival (DFS) rate was significantly higher in the IIA and IIIA patients than the IIIB and IIIC patients (72% and 100% vs 48.1% and 11.2%, respectively. p<0.001). The 5-year overall survival (OS) rate was also significantly different between in the IIA/IIIA patients and the IIIB/IIIC (67.3%/100% vs 48.4%/22.3%. p<0.001). However, the difference in DFS or OS between the oral doxifluridine group and the Mayo Clinic regimen group was not significant. Cox regression multivariate analyses showed that the new AJCC stage and tumor differentiation were significant independent prognostic factors in DFS and OS.

Conclusion

These results support that the new AJCC staging system is superior to Dukes' staging system in the prognostic stratification. Regarding DFS and OS, oral doxifluridine is comparable to the standard Mayo Clinic regimen in rectal cancer patients when combined with postoperative chemoradiation. Stage IIIC patients should be selected for aggressive therapy as they have a dismal prognosis.

Citations

Citations to this article as recorded by

Emerging Roles of Circulating Tumor DNA for Increased Precision and Personalization in Radiation Oncology
Noah Earland, Kevin Chen, Nicholas P. Semenkovich, Pradeep S. Chauhan, Jose P. Zevallos, Aadel A. Chaudhuri
Seminars in Radiation Oncology.2023; 33(3): 262. CrossRef
Development and validation of a competitive risk model in patients with rectal cancer: based on SEER database
Ruobing Hu, Xiuling Li, Xiaomin Zhou, Songze Ding
European Journal of Medical Research.2023;[Epub] CrossRef
miR-663b promotes colorectal cancer progression by activating Ras/Raf signaling through downregulation of TNK1
Sen Hong, Zhenkun Yan, Helei Wang, Lei Ding, Yumei Song, Miaomiao Bi
Human Cell.2020; 33(1): 104. CrossRef
Current controversy, confusion, and imprecision in the use and interpretation of rectal MRI
Marc J. Gollub, Chandana Lall, Neeraj Lalwani, Michael H. Rosenthal
Abdominal Radiology.2019; 44(11): 3549. CrossRef
Prognostic significance of CD168 overexpression in colorectal cancer
Ke Wang, Tao Zhang
Oncology Letters.2016; 12(4): 2555. CrossRef
Safety of Early Chemotherapy after a Laparoscopic Colorectal Cancer Resection: A Case-Control Study
Seung Ho Shin, Sun-Il Lee, Dong-Jin Choi, Si-Uk Woo, Jin Kim, Byung-Wook Min, Hong-Young Moon, Seon Hahn Kim
Journal of the Korean Society of Coloproctology.2009; 25(6): 429. CrossRef

9,902 View
46 Download
6 Crossref

Oxaliplatin with Biweekly, Low Dose Leucovorin and Bolus and Continuous Infusion 5-fluorouracil (Modified FOLFOX 4) as First-line Therapy for Patients with Metastatic Colorectal Cancer: Hyuk-Chan Kwon, Kyoung Tae Kim, Shin Ae Lee, Jong-Sung Park, Sung-Hyun Kim, Jae-Seok Kim, Hyo Jin Kim; Cancer Res Treat. 2004;36(2):115-120. Published online April 30, 2004; DOI: https://doi.org/10.4143/crt.2004.36.2.115

Abstract PDF PubReader ePub

Purpose

To determine the activity and toxicities of low dose leucovorin (LV) plus fluorouracil (5-FU) regimen, combined with oxaliplatin every two weeks (modified FOLFOX 4), as a first-line therapy for patients with metastatic colorectal cancer.

Materials and Methods

Between March 2001 and August 2003, fifty-five patients were enrolled in this study. Patients were treated with oxaliplatin 85 mg/m² as a 2-hour infusion at days 1 plus LV 20 mg/m² over 10 minutes, followed by 5-FU bolusa 400 mg/m² bolus and 22 hour continuous infusion of 600 mg/m² 5-FU at day 1~2. This treatment was repeated in 2 week intervals.

Results

The objective response rate was 40% on an intent-to-treatment analysis. Three patients (6%) demonstrated a complete response and nineteen patients (38%) showeda partial response. Sixteen patients (32%) showed a stable disease and eleven patients (22%) progressed during the course of the treatment. The median time to progression and overall survival time wereas 6.6 months (95% CI: 4.98~8.02 months) and the median overall survival time was 17.0 months (95% CI: 9.15~24.85 months) from the start of the chemotherapy, respectively. A total of 275 cycles were analyzed for toxicity. Major hematologic toxicities included grade 1~2 anemia (23.5%), neutropenia (25.3%) and thrombocytopenia (10.6%). There were only 2 cycles of neutropenic fever. The most common non-hematologic toxicities were grade 1~2 nausea/vomiting (10.9%), diarrhea (9.1%) and grade 1 neuropathy (18.0%). There was no treatment related death.

Conclusion

The modified folfox 4 regimen is safe and effective regimen as a first-line therapy in advanced colorectal cancer patients.

Citations

Citations to this article as recorded by

A Phase II Study of Modified FOLFOX4 for Colorectal Cancer Patients with Peritoneal Carcinomatosis
Dong Hyun Lee, Sung Yong Oh, Yu Rim Lee, Seok Jae Huh, Hyun Hwa Yoon, Sung Hyun Kim, Suee Lee, Ji Hyun Lee, Young Kim, Hyo-Jin Kim, Hyuk-Chan Kwon
Cancer Research and Treatment.2011; 43(4): 225. CrossRef
Outpatient-basis Chemotherapy of Oxaliplatin, 5-fluorouracil, and Leucovorin as First-line Treatment for Patients with Metastatic or Recurrent Colorectal Cancer
Joon Ho Moon, Jong Gwang Kim, Sang Kyun Sohn, Jin Ho Baek, Yoon Young Cho, Yee Soo Chae, Byung Min Ahn, Shi Nae Kim, Soo Jung Lee, In Taek Lee, Gyu Seog Choi, Soo Han Jun
Journal of Korean Medical Science.2007; 22(3): 400. CrossRef
Oxaliplatin/5-FU without Leucovorin Chemotherapy in Metastatic Colorectal Cancer
Byoung Yong Shim, Kang Moon Lee, Hyeon-Min Cho, Hyun Jin Kim, Hong Joo Cho, Jinmo Yang, Jun-Gi Kim, Hoon-Kyo Kim
Cancer Research and Treatment.2005; 37(4): 212. CrossRef
Combination Chemotherapy of Oxaliplatin, 5-Fluorouracil and Low Dose Leucovorin in Patients with Advanced Colorectal Cancer
Yoon Mi Shin, Hae Suk Han, Seong Woo Lim, Byung Chul Kim, Kyung Suck Cheoi, Young Ook Eum, Seung Taek Kim, Ki Hyeong Lee
Cancer Research and Treatment.2005; 37(5): 284. CrossRef
Oxaliplatin with Biweekly Low Dose Leucovorin and Bolus and Continuous Infusion of 5-fluorouracil (Modified FOLFOX 4) as a Salvage Therapy for Patients w ith Advanced G astric Cancer
Sung-Hwan Suh, Hyuk-Chan Kwon, Ji-Hoon Jo, Young-Rak Cho, Bong-Gun Seo, Dong-Mee Lee, Sung-Hyun Kim, Jae-Seok Kim, Hyo-Jin Kim
Cancer Research and Treatment.2005; 37(5): 279. CrossRef
Oxaliplatin: Is It a New Standard Weapon for Colorectal Cancer?
Si-Young Kim
Cancer Research and Treatment.2004; 36(2): 91. CrossRef

10,461 View
72 Download
6 Crossref

A 21-day Schedule of Gemcitabine and Cisplatin Administration in the Treatment of Advanced Non-Small Cell Lung Carcinoma: a Phase II Study: Jong-Sung Park, Chang-Min Lee, Shin-Ae Lee, Chang-kil Jung, Sung-Hyun Kim, Hyuk-Chan Kwon, Jae-Seok Kim, Hyo-Jin Kim; Cancer Res Treat. 2004;36(1):62-67. Published online February 29, 2004; DOI: https://doi.org/10.4143/crt.2004.36.1.62

Abstract PDF PubReader ePub: Purpose
To evaluate the efficacy and toxicity of gemcitabine and cisplatin combination chemotherapy, we conducted a phase II study of this regimen in patients with advanced non-small cell lung carcinoma (NSCLC).
Materials and Methods
From June 2001 to August 2003, 36 chemotherapy-naive patients with stage IIIB or IV NSCLC were enrolled. The median age was 59 years (range, 42 to 75 years), and performance status was 0 or 1. Eleven patients had stage IIIB disease, and 25 patients had stage IV disease. 1,000 mg/m² of gemcitabine was administered on day 1 & 8, and 60 mg/m² of cisplatin was administered on day 1. Each cycle was repeated every 21 days.
Results
Everyone subject who participated were assessable. A total of 160 cycles of chemotherapy were delivered, and the median number of chemotherapy courses was 3.5 (range, 2 to 9). Two patients (5.6%) achieved a complete response, and 14 patients (38.9%) achieved a partial response. The overall response rate was 44.5% (95% confidence interval [CI], 32.5 to 56.5%). The median follow-up duration was 9.3 months. The median time to disease progression was 8.6 months (95% CI 7.4 to 9.9 months), and median survival time was 12.2 months (95% CI, 10.5 to 12.9 months). Grade 3/4 neutropenia occurred in 9 patients (25.0%), neutropenic fever occurred in 3 patients (8.3%), and grade 3/4 thrombocytopenia occurred in 7 patients (19.5%). Mild forms of non-hematologic toxicities, such as nausea, vomiting or skin reactions, were observed.
Conclusion
The combination of gemcitabine and cisplatin in a 21-day schedule is an effective regimen for patients with NSCLC in its advanced stages.

8,943 View
57 Download

First
Prev
Page of 1
Next
Last

Search